<p>加利福尼亞州南舊金山，2025 年 12 月 10 日（全球新聞通訊社）——Denali Therapeutics Inc.（納斯達克代碼：DNLI）今天宣佈其承銷的公開發行價格為 9,142,857 股普通股，公眾發行價格為每股 17.50 美元，並且為了某些投資者提供預先融資的認股權證，以購買 2,285,714 股普通股，價格為每個預先融資的認股權證 17.49 美元，這代表了每股普通股的公眾發行價格減去每個預先融資的認股權證的 0.01 美元行使價格。所有股份和預先融資的認股權證均由 Denali Therapeutics 出售。此外，Denali Therapeutics 已授予承銷商一個 30 天的選擇權，以購買最多 1,714,285 股其普通股。Denali Therapeutics 預計在扣除承銷折扣和佣金及其他發行費用之前，將獲得約 2 億美元的總毛收益，並且不包括承銷商選擇購買額外股份的任何行使。該發行預計將在 2025 年 12 月 11 日左右完成，具體取決於滿足慣常的交割條件。</p>
<p>高盛公司、摩根大通證券公司、摩根士丹利公司和傑富瑞公司作為此次發行的聯合賬簿管理人。H.C. Wainwright &amp; Co., LLC 和 B. Riley Securities, Inc.作為此次發行的共同管理人。</p>
<p>Denali Therapeutics 提交了一份 S-3 表格的註冊聲明，該聲明在 2025 年 2 月 27 日提交給 SEC 時自動生效，並於 2025 年 12 月 9 日提交了與此次發行相關的初步招股説明書補充和隨附招股説明書。與此次發行相關的最終招股説明書補充和隨附招股説明書也將提交給 SEC。這些文件可以通過 SEC 的網站 www.sec.gov 免費獲取。</p>
<p>一旦可用，與此次發行相關的最終招股説明書補充和隨附招股説明書的副本也可以從以下地址獲得：</p>
<p>高盛公司，注意：招股説明書部，200 West Street, New York, NY 10282，電話：1-866-471-2526，傳真：212-902-9316，電子郵件：prospectus-ny@ny.email.gs.com；摩根大通證券公司，c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717，電子郵件：prospectus-eq_fi@jpmchase.com 和 postsalemanualrequests@broadridge.com；摩根士丹利公司，注意：招股説明書部，180 Varick Street, 2nd Floor, New York, NY 10014，電話：1-866-718-1649，電子郵件：prospectus@morganstanley.com；傑富瑞公司，注意：股權承銷招股説明書部，520 Madison Avenue, New York, New York 10022，電話：（877）821-7388，電子郵件：Prospectus_Department@Jefferies.com。</p>
<p>本新聞稿不構成出售要約或購買要約的招攬，也不會在任何州或其他管轄區進行這些證券的銷售，除非在該州或管轄區的證券法下注冊或合格之前，該要約、招攬或銷售是非法的。</p>
<p><strong>關於 Denali Therapeutics</strong></p>
<p>Denali Therapeutics 是一家生物技術公司，開創了一種新型生物治療藥物，旨在利用其專有的 TransportVehicle™平台跨越血腦屏障。憑藉經過臨牀驗證的遞送平台和不斷增長的治療候選藥物組合，Denali Therapeutics 正朝着提供有效藥物的目標邁進，以改變生活在神經退行性疾病、溶酶體儲存疾病和其他嚴重疾病患者的生活。</p>
<p><strong>前瞻性聲明</strong></p>
<p>本新聞稿包含根據聯邦證券法的定義的前瞻性聲明。這些聲明涉及風險和不確定性，可能導致實際結果與預期結果有重大差異，包括但不限於，Denali Therapeutics 是否能夠通過普通股和預先融資的認股權證的銷售籌集資金或完成此次發行、發行的最終條款、滿足慣常的交割條件、市場條件、預期的發行收益的使用，這可能因市場條件或其他原因而變化，以及美國或國際上的一般經濟、行業或政治條件的影響。與此次發行、Denali Therapeutics 及其業務相關的其他風險和不確定性可以在 Denali Therapeutics 最近提交給 SEC 的當前、季度和年度報告的 “風險因素” 部分以及與此次發行相關的初步招股説明書補充和隨附招股説明書中找到。Denali Therapeutics 不承擔更新或修訂任何前瞻性聲明的責任或義務。</p>
<p><strong>投資者關係聯繫人：</strong></p>
<p>勞拉·漢森，博士。</p>
<p>投資者關係副總裁</p>
<p><strong>hansen@dnli.com</strong></p>
<p><strong>媒體聯繫人：</strong></p>
<p>艾琳·帕頓</p>
<p>企業傳播</p>
<p><strong>epatton@dnli.com</strong></p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RVNU9UZzRPU00zTXpFMU1URTVJekl3T1RNME5qZz0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RVNU9UZzRPU00zTXpFMU1URTVJekl3T1RNME5qZz0"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/ZTAzOGViMTEtMjY4OC00ODhkLTk5ODItZTRjMTJjMjRkODQ5LTExMDUwMzktMjAyNS0xMi0xMC1lbg==/tiny/Denali-Therapeutics-Inc-.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/ZTAzOGViMTEtMjY4OC00ODhkLTk5ODItZTRjMTJjMjRkODQ5LTExMDUwMzktMjAyNS0xMi0xMC1lbg==/tiny/Denali-Therapeutics-Inc-.png"/></p>

DNLI

<p>Denali Therapeutics 宣佈以每股 17.50 美元的價格公開發行 9,142,857 股普通股，並以每股 17.49 美元的價格發行 2,285,714 股預付認股權證。此次發行旨在籌集約 2 億美元，預計於 2025 年 12 月 11 日完成。高盛、摩根大通、摩根士丹利和傑富瑞負責管理此次發行。該公司已向美國證券交易委員會（SEC）提交了必要文件，並在前瞻性聲明中強調了風險</p>

<p>SOUTH SAN FRANCISCO, Calif., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI) today announced the pricing of its underwritten public offering of 9,142,857 shares of its common stock at a price to the public of $17.50 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 2,285,714 shares of common stock at a price of $17.49 per pre-funded warrant, which represents the per share public offering price of each share of common stock less the $0.01 per share exercise price for each pre-funded warrant. All of the shares and pre-funded warrants are to be sold by Denali Therapeutics. In addition, Denali Therapeutics has granted the underwriters a 30-day option to purchase up to an additional 1,714,285 shares of its common stock. Denali Therapeutics expects to receive total gross proceeds of approximately $200 million before deducting underwriting discounts and commissions and other offering expenses and excluding any exercise of the underwriters’ option to purchase additional shares. The offering is expected to close on or about December 11, 2025, subject to satisfaction of customary closing conditions.</p>
<div class="lb-trans"><p>加利福尼亞州南舊金山，2025 年 12 月 10 日（全球新聞通訊社）——Denali Therapeutics Inc.（納斯達克代碼：DNLI）今天宣佈其承銷的公開發行價格為 9,142,857 股普通股，公眾發行價格為每股 17.50 美元，並且為了某些投資者提供預先融資的認股權證，以購買 2,285,714 股普通股，價格為每個預先融資的認股權證 17.49 美元，這代表了每股普通股的公眾發行價格減去每個預先融資的認股權證的 0.01 美元行使價格。所有股份和預先融資的認股權證均由 Denali Therapeutics 出售。此外，Denali Therapeutics 已授予承銷商一個 30 天的選擇權，以購買最多 1,714,285 股其普通股。Denali Therapeutics 預計在扣除承銷折扣和佣金及其他發行費用之前，將獲得約 2 億美元的總毛收益，並且不包括承銷商選擇購買額外股份的任何行使。該發行預計將在 2025 年 12 月 11 日左右完成，具體取決於滿足慣常的交割條件。</p>
</div><p>Goldman Sachs &amp; Co. LLC, J.P. Morgan Securities LLC, Morgan Stanley &amp; Co. LLC and Jefferies LLC are acting as joint book-running managers for the offering. H.C. Wainwright &amp; Co., LLC and B. Riley Securities, Inc. are acting as co-managers for the offering.</p>
<div class="lb-trans"><p>高盛公司、摩根大通證券公司、摩根士丹利公司和傑富瑞公司作為此次發行的聯合賬簿管理人。H.C. Wainwright &amp; Co., LLC 和 B. Riley Securities, Inc.作為此次發行的共同管理人。</p>
</div><p>Denali Therapeutics filed a Registration Statement on Form S-3, which was automatically effective upon filing with the SEC on February 27, 2025, and has filed a preliminary prospectus supplement and accompanying prospectus relating to the offering on December 9, 2025. A final prospectus supplement and accompanying prospectus relating to the offering will also be filed with the SEC. These documents can be accessed for free through the SEC’s website at www.sec.gov.</p>
<div class="lb-trans"><p>Denali Therapeutics 提交了一份 S-3 表格的註冊聲明，該聲明在 2025 年 2 月 27 日提交給 SEC 時自動生效，並於 2025 年 12 月 9 日提交了與此次發行相關的初步招股説明書補充和隨附招股説明書。與此次發行相關的最終招股説明書補充和隨附招股説明書也將提交給 SEC。這些文件可以通過 SEC 的網站 www.sec.gov 免費獲取。</p>
</div><p>When available, copies of the final prospectus supplement and the accompanying prospectus relating to this offering may also be obtained from:</p>
<div class="lb-trans"><p>一旦可用，與此次發行相關的最終招股説明書補充和隨附招股説明書的副本也可以從以下地址獲得：</p>
</div><p>Goldman Sachs &amp; Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, telephone: 1-866-471-2526, fax: 212-902-9316, email: prospectus-ny@ny.email.gs.com; J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, email: prospectus-eq_fi@jpmchase.com and postsalemanualrequests@broadridge.com; Morgan Stanley &amp; Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014, telephone: 1-866-718-1649, email: prospectus@morganstanley.com; Jefferies LLC, Attn: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, New York 10022, telephone: (877) 821-7388, email: Prospectus_Department@Jefferies.com.</p>
<div class="lb-trans"><p>高盛公司，注意：招股説明書部，200 West Street, New York, NY 10282，電話：1-866-471-2526，傳真：212-902-9316，電子郵件：prospectus-ny@ny.email.gs.com；摩根大通證券公司，c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717，電子郵件：prospectus-eq_fi@jpmchase.com 和 postsalemanualrequests@broadridge.com；摩根士丹利公司，注意：招股説明書部，180 Varick Street, 2nd Floor, New York, NY 10014，電話：1-866-718-1649，電子郵件：prospectus@morganstanley.com；傑富瑞公司，注意：股權承銷招股説明書部，520 Madison Avenue, New York, New York 10022，電話：（877）821-7388，電子郵件：Prospectus_Department@Jefferies.com。</p>
</div><p>This press release does not constitute an offer to sell or a solicitation of an offer to buy, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation, or sale would be unlawful before registration or qualification under the securities laws of that state or jurisdiction.</p>
<div class="lb-trans"><p>本新聞稿不構成出售要約或購買要約的招攬，也不會在任何州或其他管轄區進行這些證券的銷售，除非在該州或管轄區的證券法下注冊或合格之前，該要約、招攬或銷售是非法的。</p>
</div><p><strong>About Denali Therapeutics</strong></p>
<div class="lb-trans"><p><strong>關於 Denali Therapeutics</strong></p>
</div><p>Denali Therapeutics is a biotechnology company pioneering a new class of biotherapeutics designed to cross the blood-brain barrier using its proprietary TransportVehicle™ platform. With a clinically validated delivery platform and a growing portfolio of therapeutic candidates across all stages of development, Denali Therapeutics is advancing toward its goal of delivering effective medicines to transform the lives of people living with neurodegenerative, lysosomal storage and other serious diseases.</p>
<div class="lb-trans"><p>Denali Therapeutics 是一家生物技術公司，開創了一種新型生物治療藥物，旨在利用其專有的 TransportVehicle™平台跨越血腦屏障。憑藉經過臨牀驗證的遞送平台和不斷增長的治療候選藥物組合，Denali Therapeutics 正朝着提供有效藥物的目標邁進，以改變生活在神經退行性疾病、溶酶體儲存疾病和其他嚴重疾病患者的生活。</p>
</div><p><strong>Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性聲明</strong></p>
</div><p>This press release contains forward-looking statements within the meaning of the federal securities laws. These statements involve risks and uncertainties that could cause actual results to differ materially, including, but not limited to, whether or not Denali Therapeutics will be able to raise capital through the sale of shares of common stock and pre-funded warrants or consummate the offering, the final terms of the offering, the satisfaction of customary closing conditions, prevailing market conditions, the anticipated use of the proceeds of the offering which could change as a result of market conditions or for other reasons, and the impact of general economic, industry or political conditions in the United States or internationally. Additional risks and uncertainties relating to the offering, Denali Therapeutics and its business can be found under the heading “Risk Factors” in Denali Therapeutics’ most recent current, quarterly and annual reports filed with the SEC and in the preliminary prospectus supplement and accompanying prospectus relating to the offering to be filed with the SEC. Denali Therapeutics assumes no duty or obligation to update or revise any forward-looking statements for any reason.</p>
<div class="lb-trans"><p>本新聞稿包含根據聯邦證券法的定義的前瞻性聲明。這些聲明涉及風險和不確定性，可能導致實際結果與預期結果有重大差異，包括但不限於，Denali Therapeutics 是否能夠通過普通股和預先融資的認股權證的銷售籌集資金或完成此次發行、發行的最終條款、滿足慣常的交割條件、市場條件、預期的發行收益的使用，這可能因市場條件或其他原因而變化，以及美國或國際上的一般經濟、行業或政治條件的影響。與此次發行、Denali Therapeutics 及其業務相關的其他風險和不確定性可以在 Denali Therapeutics 最近提交給 SEC 的當前、季度和年度報告的 “風險因素” 部分以及與此次發行相關的初步招股説明書補充和隨附招股説明書中找到。Denali Therapeutics 不承擔更新或修訂任何前瞻性聲明的責任或義務。</p>
</div><p><strong>Investor Relations Contact:</strong></p>
<div class="lb-trans"><p><strong>投資者關係聯繫人：</strong></p>
</div><p>Laura Hansen, Ph.D.</p>
<div class="lb-trans"><p>勞拉·漢森，博士。</p>
</div><p>Vice President, Investor Relations</p>
<div class="lb-trans"><p>投資者關係副總裁</p>
</div><p><strong>hansen@dnli.com</strong></p>
<div class="lb-trans"><p><strong>hansen@dnli.com</strong></p>
</div><p><strong>Media Contact:</strong></p>
<div class="lb-trans"><p><strong>媒體聯繫人：</strong></p>
</div><p>Erin Patton</p>
<div class="lb-trans"><p>艾琳·帕頓</p>
</div><p>Corporate Communications</p>
<div class="lb-trans"><p>企業傳播</p>
</div><p><strong>epatton@dnli.com</strong></p>
<div class="lb-trans"><p><strong>epatton@dnli.com</strong></p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RVNU9UZzRPU00zTXpFMU1URTVJekl3T1RNME5qZz0" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTU5OTg4OSM3MzE1MTE5IzIwOTM0Njg="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/ZTAzOGViMTEtMjY4OC00ODhkLTk5ODItZTRjMTJjMjRkODQ5LTExMDUwMzktMjAyNS0xMi0xMC1lbg==/tiny/Denali-Therapeutics-Inc-.png" alt="" original-src="https://ml.globenewswire.com/media/ZTAzOGViMTEtMjY4OC00ODhkLTk5ODItZTRjMTJjMjRkODQ5LTExMDUwMzktMjAyNS0xMi0xMC1lbg==/tiny/Denali-Therapeutics-Inc-.png"/></p>

Denali Therapeutics 宣佈普通股和預付款認股權證公開發行的定價 | DNLI 股票新聞